Quoin Pharmaceuticals Ltd DRC (NASDAQ:QNRX) — Stock Price
Quoin Pharmaceuticals Ltd DRC (NASDAQ:QNRX) is currently trading at $5.36 USD, up 11.90% today. Over the past 52 weeks, shares have ranged between $3.25 and $22.30. This page tracks Quoin Pharmaceuticals Ltd DRC's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Quoin Pharmaceuticals Ltd DRC market cap and net worth.
Quoin Pharmaceuticals Ltd DRC (QNRX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Quoin Pharmaceuticals Ltd DRC's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Quoin Pharmaceuticals Ltd DRC Income Statement — Revenue, Profit & Earnings by Year
Quoin Pharmaceuticals Ltd DRC's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $100.79K | $100.47K | $103.44K | $103.64K | $104.11K |
| Gross Profit | $-100.79K | $-100.47K | $-103.44K | $-103.64K | $-104.11K |
| Research & Development | $9.80 Million | $3.60 Million | $3.31 Million | $2.67 Million | $1.56 Million |
| SG&A | $6.49 Million | $5.93 Million | $6.07 Million | $6.58 Million | $4.50 Million |
| Total Operating Expenses | $16.29 Million | $9.53 Million | $9.38 Million | $9.26 Million | $6.06 Million |
| Operating Income | $-16.29 Million | $-9.53 Million | $-9.38 Million | $-9.26 Million | $-6.06 Million |
| EBITDA | $-15.70 Million | $-8.86 Million | $-8.58 Million | $-8.56 Million | $-20.27 Million |
| EBIT | $-15.80 Million | $-8.96 Million | $-8.69 Million | $-8.67 Million | $-20.37 Million |
| Interest Expense | — | — | $0.00 | $714.08K | $1.09 Million |
| Income Before Tax | $-15.80 Million | $-8.96 Million | $-8.69 Million | $-9.38 Million | $-21.46 Million |
| Income Tax Expense | — | $-8.95 Billion | $22.38K | $-104.04K | $-12.94 Million |
| Net Income | $-15.80 Million | $-8.96 Million | $-8.69 Million | $-9.38 Million | $-21.46 Million |
Quoin Pharmaceuticals Ltd DRC Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Quoin Pharmaceuticals Ltd DRC's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $20.39 Million | $15.71 Million | $12.17 Million | $14.46 Million | $9.36 Million |
| Total Current Assets | $20.01 Million | $14.93 Million | $11.29 Million | $13.37 Million | $8.20 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $14.93 Million | $10.43 Million | $8.29 Million | $9.99 Million | $0.00 |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $7.27 Million | $6.50 Million | $6.51 Million | $7.05 Million | $8.70 Million |
| Total Current Liabilities | $5.55 Million | $4.18 Million | $3.58 Million | $3.53 Million | $4.58 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-3.82 Billion | $-3.62 Million | $-2.40 Million | $-2.86 Million | $-7.48 Million |
| Total Stockholder Equity | $13.12 Million | $9.20 Million | $5.66 Million | $7.41 Million | $657.03K |
| Retained Earnings | $-70.97 Million | $-55.17 Million | $-46.20 Million | $-37.52 Million | $-28.07 Million |
Quoin Pharmaceuticals Ltd DRC Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Quoin Pharmaceuticals Ltd DRC generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-13.54 Million | $-7.86 Million | $-7.86 Million | $-8.48 Million | $-5.72 Million |
| Capital Expenditures | $4.00 | $0.00 | $3.77 | $250.00K | $625.00K |
| Free Cash Flow | $-13.54 Million | $-7.86 Million | $-7.86 Million | $-8.73 Million | $-6.35 Million |
| Investing Cash Flow | $-4.28 Million | $-1.89 Million | $2.19 Million | $-10.15 Million | $-625.00K |
| Financing Cash Flow | $18.01 Million | $10.97 Million | $5.22 Million | $14.01 Million | $13.50 Million |
| Dividends Paid | — | — | — | $65.27 Million | — |
| Stock-Based Compensation | $1.15 Million | $1.26 Million | $1.09 Million | $764.01K | $0.00 |
| Depreciation | $100.00K | $100.00K | $103.71K | $104.04K | $104.04K |
| Change in Cash | $194.75K | $1.22 Million | $-459.43K | $-4.62 Million | $7.16 Million |
Quoin Pharmaceuticals Ltd DRC Earnings History — EPS Actual vs. Analyst Estimates
Track Quoin Pharmaceuticals Ltd DRC's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 06, 2026 | — | -1.83 | — |
| Mar 31, 2026 | -1.77 | -2.26 | +21.68% |
| Mar 26, 2026 | -1.74 | -4.02 | +56.72% |
| Nov 06, 2025 | -6.70 | -1.92 | -248.96% |
| Aug 07, 2025 | -6.28 | -6.83 | +8.05% |
| May 13, 2025 | -6.50 | -4.20 | -54.76% |
| Mar 11, 2025 | -0.28 | -0.43 | +35.33% |
| Nov 08, 2024 | -16.45 | -15.40 | -6.82% |